NCT01734824SUSPENDEDanonymous

Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo

Sponsor

Source record

Medical University of Vienna

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Indication / condition

AI-normalized

Bone Marrow Oedema Syndrome

Intervention

Source record

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Source & freshness

Source record

NCT ID

NCT01734824

Original source

ClinicalTrials.gov

Source last updated

Sep 23, 2015

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01734824

Title

Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo

Sponsor

Medical University of Vienna

Status

SUSPENDED

Phase

PHASE4

Condition raw

Bone Marrow Oedema Syndrome, High Turnover Bone Disease, Quality of Life

Condition normalized

Bone Marrow Oedema Syndrome, High Turnover Bone Disease, Quality of Life

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Target normalized

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Interventions

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Public preview

Source record

The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs.

This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01734824

Status

SUSPENDED

Phase

PHASE4

Sponsor

Medical University of Vienna

Executive brief

Investment-Ready Snapshot

The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs. This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedSep 23, 2015

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01734824

Indication

Bone Marrow Oedema Syndrome

Modality

small molecule

Target

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Intervention

Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.